Cargando…

Appropriate and inappropriate therapies in remotely monitored patients with cardiac implantable devices long-term experiences of a tertiary centre

FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: The evidence supporting the implantation of implantable cardioverter-defibrillator (ICD) in the primary prevention of sudden cardiac death (SCD) comes mostly from the times when optimal management of heart failure was not as effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Dyrbus, M, Pyka, L, Kurek, A, Niedziela, J T, Adamowicz, E, Ostrega, M, Sokola, K, Pres, D, Gasior, M, Tajstra, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207611/
http://dx.doi.org/10.1093/europace/euad122.477
Descripción
Sumario:FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: The evidence supporting the implantation of implantable cardioverter-defibrillator (ICD) in the primary prevention of sudden cardiac death (SCD) comes mostly from the times when optimal management of heart failure was not as effective as at present. Moreover, the detailed data on the long-term risk of arrhythmias in patients with ICD are scarce. PURPOSE: To present the long-term results of the remote monitoring (RM) of patients with ICD from a large, tertiary cardiovascular centre registry. METHODS: The clinical data from the time of device implantation were derived from the COMMIT-HF registry, while the follow-up data were obtained from the investigator-initiated RM registry. In brief, the registry encompasses data regarding the types of the transmissions and their contents, with particular emphasis on the occurrence of arrhythmic episodes, device interventions, as well as the data on the causes of other alert transmissions. RESULTS: In total, 1,299 patients were included in the analysis. The median follow-up duration of RM was 4.4 years, and the primary indication for implantation was ischemic cardiomyopathy (60.3%). Appropriate antitachycardia pacing (ATP) and high-voltage therapy for ventricular arrhythmias occurred in respectively 25.3% and 26.1% of patients, while inappropriate ATP and HV in respectively 11.5% and 8.7%. The prevalence of AF was 40.8%. CONCLUSIONS: In a large real-life cohort of continuously remotely monitored patients with ICDs, the percentage of patients with appropriate therapies for ventricular arrhythmias exceeded 25%. Further analyses are necessary to stratify the risk of ventricular arrhythmias in the contemporary practice. [Figure: see text] [Figure: see text]